GlassScriptPhysician profile
Granada S Neil
NPI 1609845478
$5,651.35
in general payments reported to CMS, 2019-2025
28 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $305 · 2021: $719 · 2022: $1,054 · 2023: $818 · 2024: $904 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.92 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,277.06 | 2021-2025 | |
| Alkermes, INC. | $1,036.79 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $624.45 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $428.83 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $282.88 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $269.01 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $224.22 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $209.78 | 2020-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $158.16 | 2020-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $123.99 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $112.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.36 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $85.74 | 2024 | Wegovy |
| Vanda Pharmaceuticals INC. | $83.95 | 2024-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $83.73 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $77.37 | 2020-2021 | |
| Axsome Therapeutics, INC. | $76.07 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $75.55 | 2019-2020 | |
| Lundbeck LLC | $74.68 | 2019-2023 | Rexulti |
| Tris Pharma INC | $67.63 | 2019-2022 | |
| Almatica Pharma LLC | $46.60 | 2022-2024 | Loreev Xr |
| Shire North American Group INC | $33.40 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.76 | 2024 | Horizant |
| Indivior INC. | $20.69 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.73 | 2022 | |
| Uswm, LLC | $14.88 | 2022 | |
| Adlon Therapeutics L.P. | $14.11 | 2020 | |
| Neos Therapeutics, LP | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Granada Neil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.